Resapp Health : Investor Presentation

Digital healthcare for respiratory disease

Tony Keating

Chief Executive Officer and Managing Director [e-mail]

Investor Presentation July 2017

ASX: RAP

Disclaimer

This presentation has been prepared by ResApp Health Limited ("ResApp"). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp. Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward-looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.

To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connection with, any use or reliance on this presentation or information.

This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

2

Digital healthcare for respiratory disease

• Developing the world's first clinically-tested, regulatory-cleared respiratory disease diagnostic test and management tools for smartphones

  • No additional hardware needed

• Huge global market, 700 million+ doctor visits annually for respiratory disease1

  • Unique opportunity to integrate into telehealth providers' existing platforms

  • Strong demand also seen within clinics, emergency rooms and outpatient facilities

• Compelling clinical evidence with 2,600+ patients enrolled in pediatric and adult studies

• Pediatric US FDA registration study underway at top-tier US hospitals

  • 1,245 patients enrolled with target recruitment numbers for all disease endpoints exceeded
  • Top-line results expected in July 2017

• FDA de novo submission planned for Q3 2017

1. ResApp estimate based on OECD doctor visits per capita data and assuming 10% of visits are for

respiratory disease (based on US data) 3

Company overview

Capital Structure (ASX:RAP)
Market Cap.	$198M
Share Price as of 7 July 2017	$0.30
Shares on Issue1	659M
Performance Shares2	93.75M
Options3	6.37M
Incentive Options4	46.35M
Cash Balance as of 31 March 2017	$10.3M

1. Includes 62.4M escrowed shares (until 14/7/17)

2. Issued on achieving AU$20M of annual revenue or on an acquisition

3. 4.5M, exercise price of 28c, expire 29/4/19; 1.87M, exercise price of 30c, expire 29/4/19

4. Issued to directors, staff and scientific advisory board

Board of Directors

Dr Roger Aston Non-Executive Chairman (Chairman of Regeneus, PharmAust and Immuron, Non-Exec. Director of Oncosil Medical, formerly CEO of Mayne Pharma, Cambridge Antibody, co-founder of

pSivida)

Dr Tony Keating Managing Director and CEO (formerly Director, Commercial Engagement at UniQuest, engineering management roles with Exa Corporation) Mr Brian Leedman Executive Director and VP (Non-Exec. Director of Alcidion, co-founder of Imugene and Oncosil Medical, formerly VP, IR at pSivida, former Chair of AusBiotech-WA) Mr Chris Ntoumenopoulos Non-Executive Director (Managing Director at Twenty 1 Corporate, Non-Exec. Director at Race Oncology, formerly at Citigroup, Indian Ocean Capital and CPS Capital)

Substantial Shareholders

Fidelity International: 9.23% Freeman Road: 6.84%

4